Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [<sup>18</sup>F]F-FDG in Oncology: A Systematic Review.

Details

Ressource 1Download: 34681850_BIB_BB902D9353A6.pdf (758.37 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_BB902D9353A6
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [<sup>18</sup>F]F-FDG in Oncology: A Systematic Review.
Journal
International journal of molecular sciences
Author(s)
Treglia G., Muoio B., Roustaei H., Kiamanesh Z., Aryana K., Sadeghi R.
ISSN
1422-0067 (Electronic)
ISSN-L
1422-0067
Publication state
Published
Issued date
17/10/2021
Peer-reviewed
Oui
Volume
22
Number
20
Pages
11192
Language
english
Notes
Publication types: Comparative Study ; Journal Article ; Systematic Review
Publication Status: epublish
Abstract
Several recent studies comparing radiolabeled fibroblast activation protein inhibitors (FAPI) and fluorine-18 fluorodeoxyglucose ([ <sup>18</sup> F]F-FDG) as positron emission tomography (PET) radiotracers in oncology have been published. The aim of this systematic review is to perform an updated evidence-based summary about the comparison of these PET radiotracers in oncology to better address further research in this setting. Studies or subsets of studies comparing radiolabeled FAPI and [ <sup>18</sup> F]F-FDG as PET radiotracers in oncology were eligible for inclusion in this systematic review. A systematic literature search of PubMed/MEDLINE and Cochrane library databases was performed until August 2021. Literature data about the comparison of [ <sup>18</sup> F]F-FDG and radiolabeled FAPI are rapidly increasing. Overall, taking into account radiotracer uptake and tumor-to-background uptake ratio, compared to [ <sup>18</sup> F]F-FDG PET, an equal or higher detection of primary tumors and/or metastatic lesions was usually demonstrated by using radiolabeled FAPI PET. In particular, the cancer entities with better detection rate of tumor lesions by using radiolabeled FAPI PET, compared to [ <sup>18</sup> F]F-FDG PET, were gastrointestinal tumors, liver tumors, breast cancer and nasopharyngeal carcinoma. Further comparison studies are needed to better evaluate the best field of application of radiolabeled FAPI PET.
Keywords
Endopeptidases, Fluorodeoxyglucose F18, Gallium Radioisotopes, Heterocyclic Compounds, 1-Ring/chemistry, Heterocyclic Compounds, 1-Ring/pharmacology, Humans, Medical Oncology, Membrane Proteins/antagonists & inhibitors, Neoplasms/diagnostic imaging, Positron Emission Tomography Computed Tomography/methods, FAPI, FDG, PET, cancer, fibroblast activation protein, fluorodeoxyglucose, imaging, oncology, positron emission tomography, systematic review
Pubmed
Web of science
Open Access
Yes
Create date
08/11/2021 9:43
Last modification date
23/11/2022 7:14
Usage data